Sponsor:
Richard Frye
Code:
NCT06213090
Conditions
Neurodevelopmental Disorders
Autism Spectrum Disorder
Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection
Pediatric Acute-Onset Neuropsychiatric Syndrome
Down Syndrome
Eligibility Criteria
Sex: All
Age: 0+
Healthy Volunteers: Not accepted
Brief summary:
Conditions
Neurodevelopmental Disorders
Autism Spectrum Disorder
Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection
Pediatric Acute-Onset Neuropsychiatric Syndrome
Down Syndrome
Study ID
NCT06213090
Start date
Feb 1, 2024
Status verified date
Apr, 2026
Completion date
Dec 31, 2030
Anticipated
Primary completion date
Dec 31, 2030
Anticipated
Eligibility Criteria
Sex: All
Age: 0+
Healthy Volunteers: Not accepted
Enrollment
1000 participants
Anticipated
Arms
Autism
Mitochondrial Encephalopathy
Down Syndrome
Cerebral Folate Deficiency
PANS
PANDAS
Epilepsy
ADHD
Dyslexia and other learning disabilities
Other Neurodevelopmental Disorders
Primary outcome measure
Locations
Rossignol Medical Center
Recruiting
Phoenix, Arizona, United States, 85050
Contacts
Sponsor
Richard Frye
Last update posted
Apr 16, 2026
Last verified
Apr, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Richard Frye on 2026-04-16.